Pharmazac launched the new product Vasitimb® / ezetimibe + simvastatin

Home > Χωρίς κατηγορία  > Pharmazac launched the new product Vasitimb® / ezetimibe + simvastatin

10 Apr Pharmazac launched the new product Vasitimb® / ezetimibe + simvastatin

Posted at 17:13h in Χωρίς κατηγορία by

Pharmazac launched the new product  Vasitimb / ezetimibe + simvastatin for theprevention of cardiovascular events, for hypercholesterlaemia and for theHomozygous Familial Hypercholesterolaemia.

Therapeutic Indications

Prevention of Cardiovascular Events

Vasitimb is indicated to reduce the risk of cardiovascular events  in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not.

Hypercholesterolaemia

Vasitimb® is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:

• patients not appropriately controlled with a statin alone

• patients already treated with a statin and ezetimibe

Homozygous Familial Hypercholesterolaemia (HoFH)

Vasitimb® is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g., low-density lipoprotein [LDL] apheresis).